ClinicalTrials.gg
RecruitingNCT03494946SECAIIIUpdated Feb 6, 2024

Liver Transplantation Compared to Chemotherapy in Patients With ColoRectal Cancer

An interventional study of Liver transplantation and Chemotherapy in Liver Metastases and Colorectal Cancer, sponsored by Oslo University Hospital. Recruiting at 1 site in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-06.

Sponsored by Oslo University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Dec 2016, registered Apr 2018).
  • Started Dec 2016; still recruiting 9 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 19 studies in Colorectal Neoplasms by Oslo University Hospital — 6 open to participants now, 9 under way, 1 of them phase 3. Colorectal Neoplasms · Oslo University Hospital.

Planned enrollment
11th of 16
30 · median 51
Started
2016
with 1 other
No phase
6 of 19
3 open now
Registered
12th of 19
by date

Among the 19 studies in Colorectal Neoplasms by Oslo University Hospital, this one is the 11th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2016, is one of 6 with no phase, and was the 12th registered.

Colorectal Neoplasms

6,554 studies on the registry are indexed under Colorectal Neoplasms; 1,665 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

6 of the 19 studies in Colorectal Neoplasms by Oslo University Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Colorectal Neoplasms by Oslo University Hospital, or all of them as a file.
02

Study summary

The trial is a randomized control trial. Patients are randomized between Ltx and other treatment that may include further chemotherapy, TACE, SIRT or other available treatment options. The patients will be randomized 1:1 to Ltx and chemotherapy/other treatment options.

Read the detailed description

Patients with non-resectable CRC liver metastases evaluated at the liver MDT at Oslo University Hospital, Rikshospitalet will be included in the study. Patients should have progressive disease on 1.line chemotherapy or the treatment should have been stopped due to toxicity. Patients randomized to Ltx will if applicable stop bevazicumab. All patients (both arms) will start further treatment that may include chemotherapy, TACE, SIRT or other available treatment options. Patients not receiving a donor liver graft within 3 months after listing for transplantation will be taken off the waiting list and transferred to the chemotherapy/other treatment option group. Patients randomized to Ltx and developing progressive disease beyond the inclusion/exclusion criteria during the time on the waiting list will be excluded from the study and receive best treatment option at the discretion of the treating physician.

03

Conditions studied

  • Liver Metastases
  • Colorectal Cancer

Keywords

  • Liver metastasis
  • Colorectal cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • verified adenocarcinoma in colon/rectum.
  • Liver , not amenable to liver resection
  • No signs of extra hepatic metastatic disease or local recurrence according to PET/CT scan within 6 weeks prior to the faculty meeting at the transplant unit, except patients may have resectable lung lesions all \< 15mm.
  • No signs of extra hepatic metastatic disease on CT or MRI thorax/abdomen/pelvis within 6 weeks prior to the faculty meeting at the transplant unit, except resectable lung lesions all \< 15mm.
  • No signs of extra hepatic metastatic disease on PET/CT within 6 weeks prior to the faculty meeting at the transplant unit, except patients may have resectable lung lesions all \< 15mm
  • Good performance status, 0 or 1.
  • Satisfactory blood tests >10g/dl, neutrophiles >1.0 (after any G-CSF), TRC >75, \<1.5 x upper normal level, ASAT, ALAT\<5 x upper normal level, Creatinine \<1.25 x upper normal level. Albumin above lower normal level.
  • Signed and expected cooperation of the patients for the treatment and followup must be obtained and documented according to GCP, and national/local regulations.
  • All patients should have progressive disease according to -criteria, or intolerance to 1. line chemotherapy. Patients must be randomized before evaluation 8-12 weeks after starting 2. line chemotherapy.

Exclusion criteria

Exclusion Criteria:

  • Weight loss >10% the last 6 months
  • Patient > 30
  • Previous resection of local relapse or non-hepatic within the last 2 years or resection of pulmonary or liver hilus lymph node metastases the last year.
  • Previous diagnosed bone or CNS metastatic disease or thoracic or abdominal metastatic lymph nodes.
  • Previous diagnosed cancer mammae or malignant melanoma.
  • Non resected or palliative resection of primary CRC tumor.
  • Liver metastases affecting the diaphragm determined by CT-scan and/or ultrasound examination.
  • Liver lesion>10cm
  • Three negative prognostic factors at time of randomization (CEA>80, less than 2 years from diagnosis, diameter of largest liver lesion >5.5cm).
  • Any reason why, in the opinion of the investigator, the patient should not participate.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Arm A

    Patients that suffer from Colorectal cancer and metastasis to liver that are randomized to Group A, will undergo Liver transplantation

    Procedure: Liver transplantation

  • Active comparator
    Arm B

    Patients that suffer from Colorectal cancer and metastasis to liver that are randomized to Group B, will be given chemotherapy, TACE, SIRT or other available treatment options.

    Drug: Chemotherapy

Interventions

  • ProcedureLiver transplantation
  • DrugChemotherapy

    May include chemotherapy, TACE, SIRT or other available treatment options.

    Also known as: Other treatment

06

What researchers measure

Primary outcomes

  1. Overall Survival

    To determine overall survival after Ltx compared to palliative chemotherapy/other treatment in patients with progressive disease on chemotherapy or intolerance to 1-line chemotherapy.

    Time frame: 2 years from time of randomisation

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2016 (actual). Primary completion is estimated for Jan 2027, 121 months after the start.

Of 900 non-industry interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 61. This study's planned 121 months is above that.

Counting every sponsor, half of 957 studies reached it within 31 months; a quarter within 14 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2018
First posted
Apr 11, 2018
StartActual
Dec 5, 2016
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Feb 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03494946
Responsible party
Magnus Smedman, MD (Consultant, gastrointestinal oncology, Oslo University Hospital) — Principal investigator
First posted
Apr 11, 2018
Start date
Dec 5, 2016
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Feb 6, 2024

Study contacts

Magnus Smedman, MD
Contact
torha@ous-hf.no
23026600
Maria Gjerde
Contact
mgjerde@ous-hf.no
+4723070000
Magnus Smedman, MD
principal investigator · Oslo University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion